Supported 14 Publications in 2019
1. Hoshika, S., et al. Hachimoji DNA and RNA: A genetic system with eight building blocks. (2019) Science 363, 884-887.
2. Wu CX et al. Parkinson's disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamics. J Biol Chem. (2019); 294(15):5907-5913.
3. Huang X et al. The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2. FASEB J. 2019 Apr;33(4):4814-4823.
4. Chefetz I et al. A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells. Cell Rep. 2019 Mar 12;26(11):3061-3075.e6.
5. Si Y. et al. hemical Space Overlap with Critical Protein-Protein Interface Residues in Commercial and Specialized Small-Molecule Libraries. ChemMedChem. 2019;14(1):119-31.
6. Nwani NG. et al. A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer. Cancers (Basel). 2019 Apr 8;11(4):502.
7. Fishel M. L. et al. Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer. Mol Cancer Ther. 2019 Nov;18(11):1947-1960.
8. Xu J. et al. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer. (2019). Nature Nanotechnology. (2019) 14(4):388-397.
9. Si Y. et al. Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEAD⋅Yap Protein-Protein Interaction. Cell Chem Biol. (2019) 21;26(3):378-389.e13.
10. Li Y. et al. First-generation structure-activity relationship studies of 2,3,4,9-tetrahydro-1H-carbazol-1-amines as CpxA phosphatase inhibitors. Bioorg Med Chem Lett. 2019 Jul 15;29(14):1836-1841.
11. Liu Y. et al. Sesn3 deficiency promotes carcinogen-induced hepatocellular carcinoma via regulation of the hedgehog pathway. Biochim Biophys Acta Mol Basis Dis. 2019 Oct 1;1865(10):2685-2693.
12. Kim HG. et al. The epigenetic regulator SIRT6 protects the liver from alcohol-induced tissue injury by reducing oxidative stress in mice. J Hepatol. 2019 Nov;71(5):960-969.
13. Washburn A. et al. Dual-targeting GroEL/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: A polypharmacology strategy for treating Mycobacterium tuberculosis infections. Bioorg Med Chem Lett. 2019 Jul 1;29(13):1665-1672.
14. Stevens M. et al. HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules. Bioorg Med Chem Lett. 2019 May 1;29(9):1106-1112.
Supported 11 Publications in 2020
1. Discovery and development of novel DNA-PK inhibitors by targeting the unique Ku-DNA interaction. Gavande NS, VanderVere-Carozza PS, Pawelczak KS, Mendoza-Munoz P, Vernon TL, Hanakahi LA, Summerlin M, Dynlacht JR, Farmer AH, Sears CR, Nasrallah NA, Garrett J, Turchi JJ. Nucleic Acids Res. 2020 Nov 18;48(20):11536-11550.
2. Bum-Erdene, K., Liu, D., Gonzalez-Gutierrez, G., Ghozayel, M. K., Xu, D., and Meroueh, S. O. (2020) Small-molecule covalent bond formation at tyrosine creates a binding site and inhibits activation of Ral GTPases. Proc Natl Acad Sci U S A 117, 7131-7139.
3. Evolution of insulin at the edge of foldability and its medical implications. Rege NK, Liu M, Yang Y, Dhayalan B, Wickramasinghe NP, Chen YS, Rahimi L, Guo H, Haataja L, Sun J, Ismail-Beigi F, Phillips NB, Arvan P, Weiss MA. Proc Natl Acad Sci U S A. 2020 Nov 24;117(47):29618-29628.
4. Small-Molecule Inhibitor Screen for DNA Repair Proteins. Turchi JJ, VanderVere-Carozza PS. Methods Mol Biol. 1999:217-221.
5. Shouksmith AE, Shah F, Grimard M, Geletu M, Luchman HA, Heaton WL, de Araujo ED, Berger-Becvar A, Gawel JM, Bakhshinyan D,Adile AA, VenugopalC, Johns AE, Al-Qaysi O, Lewis AM, O’Hare T, Deininger MW, Singh SK, Weiss S, Fishel ML*, and Gunning PT*. Identification and characterization of AES-135, a hydroxamic acid-based HDAC inhibitor that prolongs survival in an orthotopic mouse model of pancreatic cancer. J Med Chem. doi:10.1021/acs.jmedchem.8b01957.
6. Stevens M.;Howe, C.; Ray, A.M.; Washburn, A.; Chitre, S.; Sivinski, J.; Park, Y.; Hoang, Q.Q.; Chapman, E.; Johnson, S.M. Analogs of nitrofuran antibiotics are potent GroEL/ES inhibitor pro-drugs. Bioorg. Med. Chem. 2020, 28 (22), 115710.
7. Si Y. et al. Small-Molecule Covalent Modification of Conserved Cysteine Leads to Allosteric Inhibition of the TEAD⋅Yap Protein-Protein Interaction. Cell Chem Biol. 21;26(3):378-389.e13.
8. Xu D, Bum-Erdene K, Zhou D, Bailey B, Wan J, Fishel ML, Aryal U. Corson T, Pollok KP, Meroueh S. Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Targets Selected from Glioblastoma Genomic Data, ACS Chem Biol. 2020 Jun 19;(15(6):1424-1444.
9. A high-throughput screen identifies inhibitors of the interaction between the oncogenic transcription factor ERG and the cofactor EWS. Nicholas TR, Meng J, Greulich BM, Morris TS, Hollenhorst PC. PLoS One. 2020 Sep 11;15(9):e0238999. doi: 10.1371/journal.pone.0238999. eCollection 2020.
10. Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A Is Mediated by Replication Protein A in Ovarian Cancer. Sriramkumar S, Matthews TD, Ghobashi AH, Miller SA, VanderVere-Carozza PS, Pawelczak KS, Nephew KP, Turchi JJ, O'Hagan HM. Mol Cancer Res. 2020 Nov;18(11):1699-1710. doi: 10.1158/1541-7786.MCR-20-0396.
11. Structure-Guided Optimization of Replication Protein A (RPA)-DNA Interaction Inhibitors. Gavande NS, VanderVere-Carozza PS, Pawelczak KS, Vernon TL, Jordan MR, Turchi JJ. ACS Med Chem Lett. 2020 Jan 2;11(6):1118-1124.
Supported 9 Publications 2021 Jan - Aug
1. A new alpha-synuclein missense variant (Thr72Met) in two Turkish families with Parkinson's disease. Fevga C, Park Y, Lohmann E, Kievit AJ, Breedveld GJ, Ferraro F, de Boer L, van Minkelen R, Hanagasi H, Boon A, Wang W, Petsko GA, Hoang QQ, Emre M, Bonifati V. Parkinsonism Relat Disord. 2021 Jun 29;89:63-72. doi: 10.1016/j.parkreldis.2021.06.023. Online ahead of print.
2. OB-Folds and Genome Maintenance: Targeting Protein-DNA Interactions for Cancer Therapy. Par S, Vaides S, VanderVere-Carozza PS, Pawelczak KS, Stewart J, Turchi JJ. Cancers (Basel). 2021 Jul 3;13(13):3346. doi: 10.3390/cancers13133346. PMID: 34283091.
3. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J, Panzarino NJ, Turchi JJ, Johnson N, Jonkers J, Rothenberg E, Cantor SB. Mol Cell. 2021 Aug 5;81(15):3128-3144.e7. doi: 10.1016/j.molcel.2021.06.011. Epub 2021 Jul 2. PMID: 34216544.
4. Yuliya Dantsu, Ying Zhang and Wen Zhang*, “Synthesis and structural characterization of 2'-deoxy-2'-fluoro-L-uridine nucleic acids”, Organic Letters, 2021, 2021, 23(13), 5007–5011.
5. Caston RA, Shah F, Starcher CL, Wireman RS, Babb O, Grimard M, McGeown J, Armstrong L, Tong Y, Pili R, Rupert J, Zimmers TA, Elmi AN, Pollok KE, Motea EA, Kelley MR, Fishel ML. Combined inhibition of Ref-1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour co-culture models. J Cell Mol Med. 2021 Jan;25(2):784-800. https://doi.org/10.1111/jcmm.16132. PMID: 33274592. PMCID: PMC7812272.
6. Gampala S, Shah F, Lu X, Moon H, Babb O, Ganesh NU, Sandusky G, Hulsey E, Armstrong L, Mosely AL, Han B, Ivan M, Yeh J-R J, Kelley MR, Zhang C^, Fishel ML.^ Ref-1 redox activity alters cancer cell metabolism in pancreatic cancer: Exploiting this novel finding as a potential target. J Exp Clin Cancer Res (2021) 40:251. https://doi.org/10.1186/s13046-021-02046-x. PMID: 34376225.
7. Ray, A.M.; Salim, N.; Stevens M.; Chitre, S.; Abdeen, S.; Washburn, A.; Sivinski, J.; O’Hagan, H.M.; Chapman, E.; Johnson, S.M. Exploiting the HSP60/10 chaperonin system as a chemotherapeutic target for colorectal cancer. Bioorg. Med. Chem. 2021, 40, 116129.
8. Xu, D., Bum-Erdene, K., Leth, J. M., Ghozayel, M. K., Ploug, M., and Meroueh, S. O. (2021) Small-Molecule Inhibition of the uPAR uPA Interaction by Conformational Selection. ChemMedChem 16, 377-387.
9. Bum-Erdene, K., Liu, D., Xu, D., Ghozayel, M. K., and Meroueh, S. O. (2021) Design and Synthesis of Fragment Derivatives with a Unique Inhibition Mechanism of the uPAR.uPA Interaction. ACS Med Chem Lett 12, 60-66.
Supported 18 Patents from Jan. 2019 – Aug. 2021
1. Ku inhibitors and their use (WO EP JP CA EP3463371A1)
2. Xpa inhibitor compounds and their use (WO CA CA3075734A1)
3. PYRAZOLYLACYPYRAZOLINE COMPOUNDS AND METHOD FOR TREATING PAIN (US provisional application No. 62/733,153)
4. COMPOUNDS AND METHODS TO ATTENUATE TUMOR PROGRESSION AND METASTASIS (US application No. PCT/US2019/058294)
5. .SMALL-MOLECULE ANTAGONISTS OF RAS GTPASES (US provisional application No. 62/950,259)
6. Analogs of Nitrofuran Antibiotics to Combat Resistance (IU Ref: No: 2020-135-01)
7. Compounds and methods of inhibiting bacterial chaperonin systems (PCT/US2019/059458)
8. US application No. 63/011,811, Filing Date: April 17, 2020, ANTIVIRAL DRUG TREATMENT FOR HUMAN PAPILLOMAVIRUS INFECTIONS.
9. COMPOUNDS AND METHODS TO ATTENUATE TUMOR PROGRESSION AND METASTASIS (US application No. PCT/US2019/058294)
10. SMALL-MOLECULE ANTAGONISTS OF RAS GTPASES (US provisional application No. 62/950,259)
11. Analogs of Nitrofuran Antibiotics to Combat Resistance. US Provisional Patent Application #63/048,071, filed July 2020.
12. Development of a novel theranostic SMART DNA crosslinking agent as a tumor-selective prodrug against recalcitrant cancers.
13. Patent application 63/064,963 filed Aug 13, 2020
14. Lu, T and Prabhu, L. Small molecule protein arginine methyltransferase 5 (PRMT5) inhibitors and methods of treatment. Application number 16/344,644. 1st Office Action for US 16/344,644. Filed on August 13, 2020. No. EP 17863518.1, amendment. Filed on Nov.6, 2020.
15. Lu, T, Prabhu, L., and Martin, M. Repurposing FDA-approved drugs as a novel cancer therapeutic avenue through inhibitor of PRMT5. PCT/US Patent Application PCT/US2020-067694, filed Dec 31, 2020. US Patent #11034,689, Awarded by the US Patent and Trademark Office, June 15th, 2021.
16. Molecular Designs of Glucose-Responsive and Glucose-Cleavable Insulin Analogues. Provisional Application Number: 63/104,196. Filing Date: 10/22/20 (via Indiana University)
17. Conformationally Constrained Glucagon Analogues and their Use in Glucagon-Single Chain Insulin Fusion Proteins. Provisional Application Number: 63/147,611 Filing Date: 2/9/21 (via Indiana University).
18. Molecular Designs of Glucose Sensors in Insulin Analogues. Provisional Application Number: 63/183,325. Filing Date: May 3, 2021 (via Indiana University)